Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.GRCE · Entity 7266 | Director | September 17, 2026 | September 21, 2026 |
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Director | April 30, 2025 | May 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.13 · Expires 2036-09-16 | Direct | 12,200 |
Reported balance
After 2026-09-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-17 · Grant · Acquired 12,200 · Balance 12,200 F1: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.
Matinas BioPharma Holdings, Inc.
Report date April 30, 2025 · Filed May 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2035-04-30 | Direct | 11,600 |
Reported balance
After 2025-04-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-30 · Grant · Acquired 11,600 · Balance 11,600 F1: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 21, 2026 20:22 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 12,200 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001140361-26-037246 · form4.xml · derivative · entry 1 NEUGEBOREN EDWARD · CIK 0001320873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,200 Underlying: Common Stock · 12,200 shares Expires 2036-09-16 F1 · derivative.exercise_date: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:01 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001140361-26-000967 · form4.xml · derivative · entry 1 NEUGEBOREN EDWARD · CIK 0001320873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: 25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:21 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001140361-25-018696 · form4.xml · derivative · entry 1 NEUGEBOREN EDWARD · CIK 0001320873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-09 F1 · derivative.exercise_date: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2025, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| April 30, 2025 Filed May 2, 2025 17:19 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to Buy) · Derivative | 11,600 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001641172-25-008426 · ownership.xml · derivative · entry 1 NEUGEBOREN EDWARD · CIK 0001320873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,600 Underlying: Common Stock · 11,600 shares Expires 2035-04-30 F1 · derivative.exercise_date: The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:06 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0000950170-23-071879 · ownership.xml · derivative · entry 1 NEUGEBOREN EDWARD · CIK 0001320873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Class A Common Shares · 22,500 shares Expires 2033-12-19 F1 · derivative.exercise_date: Stock options granted on 12/19/2023 under the Acasti Pharma Stock Option Plan, which 10,000 shares vest in equal monthly installments over a period of 12 months (provided that 3/12 of the options shall be deemed to have vested upon the date of grant), and 12,500 shares vest in equal quarterly installments over a period of 18 months (Provided that 1/6 of the options shall be deemed to have vested upon the date of grant). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.